Transactions

uniQure’s sale to of a portion of its royalty interest in HEMGENIX® to HealthCare Royalty and Sagard Healthcare Partners

Date Announced:
05/15/2023

client:
uniQure N.V.

Status:
Pending

Value:
Up to $400 million